登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CEACAM-1】

CEACAM-1信息

英文名称:Carcinoembryonic antigen related cell adhesion molecule 1
中文名称:癌胚抗原相关细胞粘附分子1
靶点别称:CEACAM1,Biliary glycoprotein 1,BGP,CD66a,Carcinoembryonic Antigen Related Cell Adhesion Molecule 1,CD66a Antigen,BGP1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1,Antigen CD66,BGP-1,BGPI,CEA Cell Adhesion Molecule 1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein)
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

抗体项目交易平台

项目名称 项目阶段 分子类型 分子来源 疾病领域 适应症

Licensing 项目合作

项目名称 药物类型 治疗领域 适应症 阶段 权益地区

CEACAM-1分子别名

CEACAM1,CD66a,BGP,BGP1,BGPI

CEACAM-1分子背景

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is also known as Biliary glycoprotein 1 (BGP1), CD66a, which belongs to the immunoglobulin superfamily or CEA family. CEACAM1 /CD66a contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CEACAM1 /CD66a was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 / BGP-1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.

CEACAM-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
CM-24 CM-24 (MK-6018); MK-6018; CM-24 临床二期 默沙东 卵巢癌, 实体瘤, 胃癌, 胰腺癌, 膀胱癌, 结直肠癌, 黑色素瘤, 非小细胞肺癌, 甲状腺乳头状瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定